1 / 9

Baseline Characteristics of the Trial Participants, According to Study Group* - Part I

Baseline Characteristics of the Trial Participants, According to Study Group* - Part I. PM Ridker, et al. N Engl J Med 2008;359:2195-207. Baseline Characteristics of the Trial Participants, According to Study Group* - Part II. PM Ridker, et al. N Engl J Med 2008;359:2195-207.

addison-camacho
Download Presentation

Baseline Characteristics of the Trial Participants, According to Study Group* - Part I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Baseline Characteristics of the Trial Participants, According to Study Group* - Part I PM Ridker, et al. N Engl J Med 2008;359:2195-207

  2. Baseline Characteristics of the Trial Participants, According to Study Group* - Part II PM Ridker, et al. N Engl J Med 2008;359:2195-207

  3. Lipid and High-Sensitivity C-Reactive Protein Levels during the Follow-up Period, According to Study Group* PM Ridker, et al. N Engl J Med 2008;359:2195-207

  4. Outcomes According to Study Group PM Ridker, et al. N Engl J Med 2008;359:2195-207

  5. Cumulative Incidence of Cardiovascular Events According to Study Group PM Ridker, et al. N Engl J Med 2008;359:2195-207

  6. Effects of Rosuvastatin on the Primary End Point, According to Baseline Characteristics PM Ridker, et al. N Engl J Med 2008;359:2195-207

  7. Monitored Adverse Events, Measured Laboratory Values, and Other Reported Events of Interest during the Follow-up Period* PM Ridker, et al. N Engl J Med 2008;359:2195-207

  8. Trial schematic PM Ridker, et al. N Engl J Med 2008;359:2195-207 - Online Supplemental Appendix

  9. Relationship of the proportional reduction in cardiovascular event rate and mean LDL cholesterol difference between treatment groups in published statin trials PM Ridker, et al. N Engl J Med 2008;359:2195-207 - Online Supplemental Appendix

More Related